Drug Database
Back to search

Czechia· CZ-0255635

UPLIZNA

A inebilizumab product containing inebilizumab, registered in Czechia by Amgen Europe B.V., Breda. The same ATC class is registered in 8 of our 19 countries.

ATC L04AG10

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedUPLIZNAATCL04AG10REGISTER NO.CZ-0255635PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about inebilizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Inebilizumab is registered in 8 of 19 countries.

Countries holding a registration under ATC L04AG10 (inebilizumab), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 5 of them publish a price we can compare per daily dose
Search inebilizumab products by name

Inebilizumab · ATC L04AG10

8 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Netherlands
  • Norwayprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
INEBILIZUMAB
Manufacturer
Amgen Europe B.V., Breda
Country
Czechia (CZ)
ATC code
L04AG10
ATC class
Inebilizumab
Defined daily dose
1.67 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0255635
    3X10ML
    CZK 1293926.68

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

51 interactions on record for inebilizumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check inebilizumab against other medicinesHow interaction checks work

Inebilizumab · interactions on record

51 records

  • 27 severe
  • 18 moderate
  • 6 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Inebilizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inebilizumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Uplizna
  • Norway · Uplizna

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/37e31b86-7ec2-44f5-8e12-fce571fe2939
GET /v1/drugs/37e31b86-7ec2-44f5-8e12-fce571fe2939?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF CNC SOL",
  "source": "sukl",
  "strength": "100MG",
  "pack_size": "3X10ML",
  "substance": "INEBILIZUMAB",
  "cz_kod_sukl": "0255635",
  "product_type": "BT",
  "substance_codes": "20815",
  "registration_state": "R",
  "registration_number": "EU/1/21/1602/001"
}
API referenceMCP serverPlans

See everything about inebilizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console